سعر ليناجنتا 5 مجم 10 اقراص 2026

Linajenta 5 mg: linagliptin 5 mg tablets, pack of 10 (Global Napi Pharmaceuticals, Egypt); DPP-4 inhibitor for type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in type 2 diabetes mellitus.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Nasopharyngitis (7.0% vs 6.1% with placebo) was the adverse reaction reported in at least 2% of patients and more often than placebo in pooled placebo-controlled trials.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Laboratory: increases in uric acid, lipase and amylase have been observed.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to linagliptin or any excipient (reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria or bronchial hyperreactivity).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Pancreatitis: acute pancreatitis, including fatal cases, has been reported; discontinue promptly if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypoglycaemia risk increases when combined with insulin or an insulin secretagogue (e.g. a sulfonylurea); a lower dose of these may be needed.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Serious hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions) have been reported, mostly within the first 3 months; use caution with a history of angioedema to another DPP-4 inhibitor.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Strong P-glycoprotein or CYP3A4 inducers (e.g. rifampin)Rifampin decreased linagliptin exposure; efficacy may be reduced, so alternative treatment is strongly recommended.DailyMed (U.S. National Library of Medicine)
• Insulin and insulin secretagogues (e.g. sulfonylureas)Increased risk of hypoglycaemia; lower doses of insulin or the secretagogue may be required.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are not sufficient to inform a drug-associated risk of major birth defects or miscarriage; poorly controlled diabetes in pregnancy carries maternal and fetal risks; no adverse developmental effects in rats at clinically relevant exposure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No information on linagliptin in human milk or effects on the breastfed infant; linagliptin is present in rat milk. Weigh the benefits of breastfeeding against the mother's clinical need.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Linagliptin: Inhibits DPP-4, the enzyme that degrades GLP-1 and GIP, increasing active incretin levels, glucose-dependent insulin release and lowering glucagon (US label 12.1).